Moving on to another class of targeted therapies, EGFR-tyrosine kinase inhibitors (TKIs) are small-molecule agents that bind to the intracellular catalytic domain of the epidermal growth factor receptor (EGFR), preventing it from phosphorylating and activating downstream signaling cascades involved in cancer cell proliferation and survival (17). The gene discussed is EGFR; the disease is cancer.